Repare Therapeutics (RPTX) shares Q2 2025 business and financial update

Rhea-AI Filing Summary

Repare Therapeutics Inc. filed a current report to note that it issued a press release on August 8, 2025 detailing recent business highlights and its financial results for the three and six months ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this report.

The company clarifies that the information in this report and the accompanying exhibits is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced, and that information on its website is not part of this disclosure.

0001808158false00-000000000018081582025-08-082025-08-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 08, 2025

Repare Therapeutics Inc.

(Exact name of Registrant as Specified in Its Charter)

Quebec			001-39335	Not applicable
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
7171 Frederick-Banting, Building 2 Suite 270
St-Laurent, Quebec, Canada				H4S 1Z9
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857 412-7018

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common shares, no par value		RPTX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 8, 2025, Repare Therapeutics Inc. (the "Company") issued a press release announcing its recent business highlights and financial results for the three and six months ended June 30, 2025. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained herein and in the accompanying exhibits is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

The Company’s website and any information contained on the Company’s website are not incorporated into this Current Report on Form 8-K

Item 9.01 Financial Statements and Exhibits.

Exhibit
No.		Description
99.1		Press Release dated August 8, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			REPARE THERAPEUTICS INC.
Date:	August 8, 2025	By:	/s/ Steve Forte
			Steve Forte President, Chief Executive Officer and Chief Financial Officer

FAQ

What did Repare Therapeutics Inc. (RPTX) disclose in this 8-K?

Repare Therapeutics Inc. disclosed that it issued a press release on August 8, 2025 providing recent business highlights and financial results for the three and six months ended June 30, 2025, which is attached as Exhibit 99.1.

Which period do the Repare Therapeutics (RPTX) results in the press release cover?

The press release covers Repare Therapeutics Inc.’s financial results for the three and six months ended June 30, 2025.

Where can investors find the detailed Q2 2025 results for Repare Therapeutics (RPTX)?

The detailed results are contained in the press release dated August 8, 2025, which is attached to the report as Exhibit 99.1.

Is the Repare Therapeutics (RPTX) press release automatically part of other SEC filings?

No. The company states that the information in this report and its exhibits is not incorporated by reference into other Securities Act or Exchange Act filings unless specifically referenced.

Does Repare Therapeutics (RPTX) include its website information in this disclosure?

No. The company specifies that its website and any information on it are not incorporated into this report.

What exhibits are attached to this Repare Therapeutics (RPTX) 8-K?

The report includes Exhibit 99.1, the press release dated August 8, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.